Jarrard Lab
- David F Jarrard, MD
- Bing Yang, MD, PhD
- Tanaya Purohit, MS
- Zachery Schultz, BS
- Kayla Bahr, BS
- Undergraduate Students
David F Jarrard, MD (Principal investigator)
jarrard@urology.wisc.edu
MD, University of Virginia School of Medicine, Charlottesville, VA.
Junior Residency in General Surgery, University of Chicago, Chicago, IL.
Residency in Urology, University of Chicago, Chicago, IL.
Fellow in Urologic Oncology, American Foundation for Urologic Disease, Johns Hopkins University, Baltimore, MD.
Dr. Jarrard a tenured Professor, Vice Chair for the Department of Urology, and Deputy Director at the UW Carbone Cancer Center at the University of Wisconsin. He is a physician-scientist with expertise in clinical urologic cancer management, clinical trials, and translational research. He currently holds the John Livesey Chair in Urologic Oncology and am a member of the Wisconsin Institute for Discovery Epigenetics program. Service on several national committees includes prostate cancer guidelines panels for the National Comprehensive Cancer Network (NCCN) and the American Urological Association (AUA). National leadership roles have included past-President of the AUA North Central Section, the Society for Basic Urologic Research (SBUR), and Society for Academic Urology (SAU) and co-Chair of the Research, Education, and Conferences Committee (RECCC) for the AUA. He has wide-ranging experience serving as a reviewer and chair.
His clinical work concentrates on the surgical treatment of prostate cancer and improving cancer detection and outcomes. He serves as the urology co-PI on the paradigm-shifting CHAARTED trial of docetaxel and androgen deprivation therapy (ADT) for metastatic HSPC, and on other trials in chemoprevention and advanced prostate cancer management.
Dr. Jarrard is the principle investigator for the University of Wisconsin Prostate Cancer Special Program of Research Excellence (SPORE), a highly competitive grant focused on translating research into new treatments for our patients. Other basic science and translational research interests are supported through the NIH (R01) and the Department of Defense Prostate Cancer Research Program examining epigenetic factors underlying prostate cancer progression and novel approaches to treating advanced disease. This work has led to the development of novel epigenetic and imaging biomarkers in normal tissue. Recent innovations include the recognition that androgen removal, a common treatment in advanced prostate cancer, when combined with agents targeting unique epigenetic and metabolic changes can improve cancer outcomes. He has published numerous chapters, articles, and abstracts in the field of prostate cancer. Dr. Jarrard has an extensive and enthusiastic history of mentoring graduate, undergraduate, residents, and faculty.
Bing Yang, MD, PhD (Distinguished Researcher)
yangb@urology.wisc.edu
MD, Jiamusi Medical University (China).
PhD, Nagasaki University (Japan).
Dr. Yang is the co-leader of the Jarrard laboratory and has a long record of excellence in research, mentoring and publications. Her research focuses on examining epigenetic alterations in prostate cancer and investigating epigenetic causes behind hormone treatment failure in prostate cancer.
Awards: WARF Innovation Award for developing a molecular-based method to diagnose prostate cancer.
Tanaya Purohit, MS (PhD student)
tpurohit2@wisc.edu
BSc, Biotechnology, SP Pune University (India).
Post graduate diploma in Bioinformatics, BVD University (India).
MS, Biotechnology and Entrepreneurship, New York University, New York, NY.
Ms Purohit is a PhD candidate working towards her thesis in the Jarrard lab. She is in the Cancer biology PhD program offered by the McArdle laboratory for Cancer research (Department of Oncology). Her research focuses on understanding the role of histone-modifying enzymes in prostate tumorigenesis after androgen deprivation therapy. She is also interested in exploring the link between genetic and epigenetic alterations that occur in prostate cancer progression. Outside of wet lab research, Tanaya is actively involved in UWCCC Cancer Trainee Network whose mission is to grow the involvement of trainees across the UW cancer research fields and foster a community of service. Additionally, she serves on the SMPH/UW Health Diversity Workforce and Equity Transformation committee as a trainee representative.
Zachery Schultz, BS (PhD student)
zschultz2@wisc.edu
BS, Molecular Biology, University of Wisconsin-Madison, Madison, WI
Zach is a graduate student in the Cancer Biology PhD program working towards his thesis in the Jarrard lab. His research focuses on understanding the epigenetic mechanisms involved in the progression to castration resistant prostate cancer after androgen deprivation therapy. He is also interested in identifying histone modifying enzymes that can be therapeutically targeted to improve combinatorial responses to ADT. Outside of the lab, Zach enjoys playing golf, spending time outdoors and reading.
Kayla Bahr, BS (Research Specialist)
BS in biology and a certificate in Global Health, University of Wisconsin-Madison, Madison, WI.
Kayla graduated from UW-Madison with a Bachelor of Science in Biology and a certificate in Global Health. She is a Research Specialist in the Jarrard Lab and contributes to various projects currently underway in the lab.
Mohammad Rizvi
mmrizvi@wisc.edu
BS, Biology, University of Wisconsin-Madison, Madison, WI. (2023-2027)